RRPC11 have increased expression of PHF19, a prognostic marker for myeloma, resulting in reduce chromatin accessibility and gene expression of CDKN1C. Not surprisingly these same cells exhibit a proliferation signature suggesting a regulatory role of PHF19 in RRMM patients that results in a more proliferative state. This evidence concerns the gene PHF19 and plasma cell myeloma.